中文 / CN
Deutsch / DE
日本語 / JP
한글 / KR
Contact Us
Menu
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button
>

Discovery

Integrated Discovery Platform
From Concept to IND

Monoclonal Antibody Discovery

​More than 100 monoclonal antibodies (mAbs) have been approved in clinics for treatment of cancer, autoimmune disorders, and inflammatory and infectious diseases. MAbs are also important building blocks for the design and construction of bispecific, multispecific and biparatopic antibodies, antibody drug conjugates (ADC) and CAR (chimeric antigen receptor) T-cell therapeutics. WuXi Biologics has extensive experience in the generation and lead preclinical candidate (PCC) discovery of mAbs from human, mouse, rat, alpaca, llama and rabbit covering traditional and heavy-chain-only mAbs. WuXi Biologics has established multiple core technology platforms including hybridoma, phage display, yeast display and single B cell screening approaches for mAb discovery.

Hybridoma

 

WuXi Biologics provides antibody generation through traditional hybridoma approaches using our WuXiHybrid™ advanced hybridoma-monoclonal antibody technology platform. We also offer multiple approaches for generating fully human antibodies using transgenic animals from either Ligand’s OmniAb® or Alloy Therapeutics’ ATX-Gx™ platforms. WuXi Biologics has successfully delivered 200+ therapeutic antibody discovery projects via our hybridoma platform. In addition, our team of experts have extensive experience with GPCR (G Protein-Coupled Receptor) & other difficult targets.

 

Key Features:

 

  • ​ AAALAC accredited animal facility
  • Transgenic mice/rats for fully human antibody generation
  • Multiple immunization strategies (DNA, peptide, protein, cell or combinations thereof) to generate the best-fit to targets
  • Proprietary immunization protocols to increase immune responses
  • High fusion efficiency through electrofusion
  • High throughput protein-based and cell-based screening platforms that includes five high-throughput flow cytometers and seven Biacore instruments to support screening and affinity ranking
  • Functional screen using hybridoma supernatants to increase chances of isolating functional leads

 

Phage Display

 

WuXi Biologics offers high-quality phage display library construction and customized library selection and screening services via our WuXiLiAb® human naive/synthetic phage display libraries, VHH naive libraries and antibody immune libraries. In addition, we have extensive experience for challenging targets such as GPCR (G-Protein Coupled Receptor), ion-channel, multi-subunit complex.

 

Process and Timeline:

 

WuXi Biologics has constructed human naïve libraries from 50+ donors with more than 1*1011 transformants representing nearly all of the human antibody V-gene repertoire. WuXi Biologics has also designed and constructed human synthetic libraries based on dominant germline pair of heavy and light chains with more than 1*1012 transformants. WuXi Biologics has successfully delivered 40+ antibody discovery projects based on human naive/synthetic display platform. Typical project timelines include:

 

  • Naive/synthetic library panning/screening: 2-3 months.
  • Immune library construction and screening: 3-4 months

 

 

Key Features:

 

  • In-house ready to use human naïve or synthetic libraries
  • Immune (custom) libraries: human, mouse, rat, llama, alpaca, common light chain
  • Liquid-phase, solid-phase and cell-based panning
  • Epitope guided and Avi-tag capture selections enable isolation of functionally active antibodies

 

VHH Generation

 

WuXi Biologics offers high-quality alpaca immune library construction and customized library selection and screening services. WuXi Biologics has constructed alpaca naïve libraries from 100+ alpaca donors with more than 3*10^11 transformants. We have successfully delivered 70+ VHH antibody discovery projects based on immunization and naive phage display libraries. Typical project timelines include:

 

  • Naïve library panning/screening: 2-3 months.
  • Immune library construction and screening: 3-4 months

 

 

Key Features:

 

  • Liquid-phase, solid-phase and cell-based panning
  • In-house ready to use alpaca naïve libraries
  • Multiple immunization strategies (DNA, peptide, protein, cell or combinations thereof) to generate the best-fit to targets
  • Proprietary immunization protocols to increase immune responses
  • Proprietary primer sets to achieve increased coverage of alpaca VHH gene repertoire

 

Single B Cell Screening

 

WuXi Biologics utilizes the Berkeley Lights Beacon Optofluidic® systems’ highly efficient single B cell screening methodology to identify lead monoclonal antibodies and to dramatically reduce the traditional discovery timelines.

Key Features of Single B Screen on the Beacon® Optofluidic system:

 

  • Fast screening. More than 10,000 primary B cells can be analyzed in one day
  • Multiple cell-based assays can be used for primary screening
  • Obtain antibody sequences within 2 months
  • High sequence recovery rate: >90% recombinant antibodies retain antigen binding at initial screening
  • Mouse, rat, rabbit and alpaca antibody discovery capabilities

 

Typical Single B cell Screening Timeline

 

Single B Cell Screening Process

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?

Yes, continue to proceed
No, stay on this Website